Sunday, October 18
India on Wednesday banned the X (formerly Twitter) account of the Global Times, the official mouthpiece of China’s ruling Communist Party. Additionally, the account of the Chinese news agency Xinhua News was also blocked.This comes days after the Indian Embassy in China strongly cautioned the media outlet to verify facts before posting on social media.“Dear Global Timesnews, we would recommend you verify your facts and cross-examine your sources before pushing out this kind of disinformation,” the Embassy said in a post on X, responding to the tabloid's coverage of Indian military strikes allegedly targeting Pakistan’s terror infrastructure during Operation Sindoor.ALSO READ: MEA 'categorically' rejects China's attempts to rename places in Arunachal Pradesh 121154737In a follow-
After a positive move in the precious metals, pushed by a cooling inflation, investors chose to book profits as Gold June futures contracts at MCX were trading at Rs 93,195/10 grams, lower by Rs 452 or 0.48. Silver July futures contracts were also trading lower by Rs 704 or 0.73% at Rs 96,063/kg.On Tuesday, gold and silver settled on a positive note in the domestic and international markets. Gold June futures contract settled at Rs 93,647 per 10 grams with a gain of 0.80%, and silver July futures contract settled at Rs 96,767 per kilogram with a gain of 1.49%.Gold and silver curtail the previous session’s losses and gains in the international markets after U.S. inflation cools off in April. The U.S. CPI came at 3.2% on an annual basis in April against March’s reading of 3.3% but slight
Mumbai: US President Donald Trump’s executive order to drugmakers to lower medicine prices in the US to levels other countries pay could benefit generics companies, Umang Vohra, CEO of Cipla, said on Tuesday.Trump’s order on Monday may turn the US into a “market where generic drugs will be preferred,” Vohra told analysts in an earnings call after Cipla reported a 30% year-on-year (YoY) increase in its fourth quarter net profit to Rs 1,222 crore.“We do not see that (the executive order) impacting our business at all,” he said.Cipla’s income from operations rose 9% YoY to Rs 6,730 crore in the fourth quarter, while Ebitda was up 17% at Rs 1,538 crore.For the full FY25, the company’s net profit surged 28% to Rs 5,273 crore, income from operations grew 8% to Rs 27,548 crore, an
Mumbai: US President Donald Trump’s executive order to drugmakers to lower medicine prices in the US to levels other countries pay could benefit generics companies, Umang Vohra, CEO of Cipla, said on Tuesday.Trump’s order on Monday may turn the US into a “market where generic drugs will be preferred,” Vohra told analysts in an earnings call after Cipla reported a 30% year-on-year (YoY) increase in its fourth quarter net profit to Rs 1,222 crore.“We do not see that (the executive order) impacting our business at all,” he said.Cipla’s income from operations rose 9% YoY to Rs 6,730 crore in the fourth quarter, while Ebitda was up 17% at Rs 1,538 crore.For the full FY25, the company’s net profit surged 28% to Rs 5,273 crore, income from operations grew 8% to Rs 27,548 crore, an
